Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations
Author:
Publisher
Elsevier BV
Subject
Oncology
Reference9 articles.
1. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors;Hirota;Science,1998
2. PDGFRA activating mutations in gastrointestinal stromal tumors;Heinrich;Science,2003
3. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors: a phase I study;van Osteroom;Lancet,2001
4. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumors;Heinrich;J Clin Oncol,2003
5. Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation;Wakai;Br J Cancer,2004
Cited by 160 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial;Nature Medicine;2024-01-05
2. FBXW7 regulates the sensitivity of imatinib in gastrointestinal stromal tumors by targeting MCL1;Gastric Cancer;2023-12-24
3. Unraveling the Mechanisms of Sensitivity to Anti-FGF Therapies in Imatinib-Resistant Gastrointestinal Stromal Tumors (GIST) Lacking Secondary KIT Mutations;Cancers;2023-11-09
4. Ripretinib in combination with tyrosine kinase inhibitor as a late-line treatment option for refractory gastrointestinal stromal tumors: two case reports and literature review;Frontiers in Pharmacology;2023-05-23
5. LIX1 Controls MAPK Signaling Reactivation and Contributes to GIST-T1 Cell Resistance to Imatinib;International Journal of Molecular Sciences;2023-04-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3